1-7 of 7
Hui Gao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts

Tianshu Feng, Javad Golji, Ailing Li, Xiamei Zhang, David A. Ruddy, Daniel P. Rakiec, Felipe C. Geyer, Jane Gu, Hui Gao, Juliet A. Williams, Darrin D. Stuart, Matthew J. Meyer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2421–2432.
https://doi.org/10.1158/1535-7163.MCT-19-0028
Published: 02 December 2019
View article titled, Distinct Transcriptional Programming Drive Response to MAPK Inhibition in <em>BRAF</em><sup>V600</sup>-Mutant Melanoma Patient-Derived Xenografts
Open the PDF for Distinct Transcriptional Programming Drive Response to MAPK Inhibition in <em>BRAF</em><sup>V600</sup>-Mutant Melanoma Patient-Derived Xenografts in another window
Includes: Supplementary data
Journal Articles

Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma

Vianey Gonzalez-Villasana, Cristian Rodriguez-Aguayo, Thiruvengadam Arumugam, Zobeida Cruz-Monserrate, Enrique Fuentes-Mattei, Defeng Deng, Rosa F. Hwang, Huamin Wang, Cristina Ivan, Raul Joshua Garza, Evan Cohen, Hui Gao, Guillermo N. Armaiz-Pena, Paloma del C. Monroig-Bosque, Bincy Philip, Mohammed H. Rashed, Burcu Aslan, Mumin Alper Erdogan, Yolanda Gutierrez-Puente, Bulent Ozpolat, James M. Reuben, Anil K. Sood, Craig Logsdon, Gabriel Lopez-Berestein
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (11): 2583–2594.
https://doi.org/10.1158/1535-7163.MCT-14-0028
Published: 03 November 2014
View article titled, Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma
Open the PDF for Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Christine Fritsch, Alan Huang, Christian Chatenay-Rivauday, Christian Schnell, Anupama Reddy, Manway Liu, Audrey Kauffmann, Daniel Guthy, Dirk Erdmann, Alain De Pover, Pascal Furet, Hui Gao, Stephane Ferretti, Youzhen Wang, Joerg Trappe, Saskia M. Brachmann, Sauveur-Michel Maira, Christopher Wilson, Markus Boehm, Carlos Garcia-Echeverria, Patrick Chene, Marion Wiesmann, Robert Cozens, Joseph Lehar, Robert Schlegel, Giorgio Caravatti, Francesco Hofmann, William R. Sellers
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2014) 13 (5): 1117–1129.
https://doi.org/10.1158/1535-7163.MCT-13-0865
Published: 05 May 2014
View article titled, Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Open the PDF for Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Abstract A11: Modeling drug response and resistance using patient-derived xenograft models.

Guizhi Yang, John Green, Colleen Kowal, Shawn Cogan, Roberto Velazquez, John Monahan, Joshua Korn, Nicholas Keen, Juliet Williams, Hui Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A11.
https://doi.org/10.1158/1535-7163.TARG-13-A11
Published: 01 November 2013
View article titled, Abstract A11: Modeling drug response and resistance using patient-derived xenograft models.
Journal Articles

Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer

Antonio Giordano, Hui Gao, Simone Anfossi, Evan Cohen, Michal Mego, Bang-Ning Lee, Sanda Tin, Michele De Laurentiis, Charla A. Parker, Ricardo H. Alvarez, Vicente Valero, Naoto T. Ueno, Sabino De Placido, Sendurai A. Mani, Francisco J. Esteva, Massimo Cristofanilli, James M. Reuben
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (11): 2526–2534.
https://doi.org/10.1158/1535-7163.MCT-12-0460
Published: 08 November 2012
View article titled, Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer
Open the PDF for Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B27: Correlation between TNFα and LCL161 anti‐tumor activity in patient derived xenograft models of human cancer

Brant Firestone, Colleen Conway, Guizhi Yang, Hui Gao, Dale Porter, Joanna Slisz, Dan He, Rebecca Mosher, John Monahan, Christopher Straub, Michael Morrissey, Yung‐mae Yao, Leigh Zawel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B27.
https://doi.org/10.1158/1535-7163.TARG-09-B27
Published: 10 December 2009
View article titled, Abstract B27: Correlation between TNFα and LCL161 anti‐tumor activity in patient derived xenograft models of human cancer
Journal Articles

Phase I dose escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, in combination with interferon-α for patients with solid tumors

Luis Camacho, Aung Naing, Claire Verschraegen, Funda Meric-Bernstam, David Hong, Stacy Moulder, Cataliner Gutierrez, Saneese Stephen, Chandtip Chandhasin, Hui Gao, Evans Cohen, Bang-Ning Lee, Maritza Martinez, Lawrence Akinsanmi, Razelle Kurzrock, James Reuben
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B89.
Published: 01 November 2007
View article titled, Phase I dose escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, in combination with interferon-α for patients with solid tumors